ArticleThe journal of nutrition, health & aging2024
Relationships between sarcopenia, depressive symptoms, and the risk of cardiovascular disease in Chinese population.
Article in The journal of nutrition, health & aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Association of sarcopenia with atrial fibrillation: protocol for a systematic review and meta-analysis.Systematic reviews · 2025Article
- Associations of sarcopenia with depression and suicidal ideation: the sex-specific mediating role of loneliness.BMC geriatrics · 2025Article
- The association of bone mineral density with cardiovascular disease and mortality among individuals with/without type 2 diabetes: a population-based retrospective cohort.Diabetology & metabolic syndrome · 2025Article
- High Prevalence and Clinical Correlates of Sarcopenia and Metabolic Syndrome in Outpatients with Major Depressive Disorder: A Cross-Sectional Study.Neuropsychiatric disease and treatment · 2025Article
- Association between the triglyceride-glucose-waist-to-height ratio and cardiovascular disease in Chinese adults with sarcopenia or probable sarcopenia.Frontiers in endocrinology · 2025Article
- Sarcopenia, Depressive Symptoms, and Fall Risk: Insights from a National Cohort Study in the Chinese Population.Risk management and healthcare policy · 2025Article
- The association between sarcopenic obesity and cardiometabolic multimorbidity in chinese middle-aged and older adults.The journal of nutrition, health & aging · 2024Article
- Tackling aging muscle loss throughout lesser mealworm protein supplementation.The journal of nutrition, health & aging · 2024Article
- Relationships between sarcopenia, depressive symptoms, and the risk of all-cause mortality in the Chinese population.The journal of nutrition, health & aging · 2024Article
- Additive impact of metabolic syndrome and sarcopenia on all-cause and cause-specific mortality: an analysis of NHANES.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies had indicated that sarcopenia and depressive symptoms were associated with increased risk of cardiovascular disease (CVD). The aim of present study was to evaluate the combined effect of sarcopenia and depressive symptoms on the CVD risk.
methodsA total of 11,011 participants from the China Health and Retirement Longitudinal Study 2011-2020 were included. Multivariate Cox proportional hazards regression model was used to explore the associations between sarcopenia, depressive symptoms and new-onset CVD, stroke and cardiac events.
resultsDuring the 7-year follow-up, a total of 2,388 respondents experienced CVD (including 812 stroke and 1,831 cardiac events). There is a significant additive and multiplicative interactions of sarcopenia and depressive symptoms on risk of CVD, stroke and cardiac events. Compared with those without sarcopenia and depressive symptoms, individuals with depressive sarcopenia had the highest risk of CVD, stroke and cardiac events, with the corresponding hazard ratios (95% confidence interval) were 1.43 (1.26-1.63), 1.45 (1.15-1.82) and 1.50 (1.29-1.74), respectively.
conclusionOur study indicated that there was a combined effect of sarcopenia and depressive symptoms on the risk of CVD, stroke and cardiac events. Our findings highlighted the importance of identifying sarcopenia and depressive symptoms, and intervening much earlier both in older and younger population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.